Imperial Innovations Businesses Llp investment portfolio

Aqdot develops and licenses AqFresh™, a patented supramolecular chemistry technology that captures and removes odours and volatile organic compounds from products such as non‑wovens, textiles, plastics, coatings, automotive interiors and hygiene items. Its target market is manufacturers seeking fragrance‑free, non‑toxic odor‑control solutions for consumer and industrial applications.

Autifony Therapeutics develops small‑molecule modulators of Kv3 potassium channels to create new medicines for rare genetic central nervous system disorders, including Fragile X syndrome and myoclonic epilepsy, and is extending its ion‑channel platform to broader CNS indications such as schizophrenia and hearing loss.